Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress

References

• Polaris Observatory C, Gamkrelidze I, Nguyen MH. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):383–403. doi: 10.1016/S2468-1253(18)30056-6
   PubMed Web of Science ®Google Scholar
• Razavi-Shearer D. The incidence of chronic HBV by age at the global and regional level, 2022. Parallel #17: evolving epidemiologic and natural history of chronic HBV and HDV. In: Gregory JG, editor. The liver meeting; November 2022; Washington DC: Hepatology; 2022.
   Google Scholar
• Organisation WH. Hepatitis B [fact sheet]. 2022. [cited 2022 Aug 27]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
   Google Scholar
• Global Hepatitis Report 2017. Geneva: World Health Organization. 2017.
   Google Scholar
• Lampertico P, Agarwal K, Berg T, et al. Electronic address eee, European Association for the study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370–398. doi: 10.1016/j.jhep.2017.03.021
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560–1599. doi: 10.1002/hep.29800
   PubMed Web of Science ®Google Scholar
• Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016 Jan;10(1):1–98. doi: 10.1007/s12072-015-9675-4
   PubMed Web of Science ®Google Scholar
• Baik D, Kim BW, Oh JK, et al. Costs of viral hepatitis B in the Republic of Korea, 2002-2015. J Viral Hepat. 2020 Feb;27(2):156–167. doi: 10.1111/jvh.13219
   PubMed Web of Science ®Google Scholar
• Cornberg M, Lok AS, Terrault NA, et al. Guidance for design and endpoints of clinical trials in chronic hepatitis B—report from the 2019 EASL-AASLD HBV treatment endpoints conference. Hepatology. 2019 Nov 12;71(3):1070–1092. doi: 10.1002/hep.31030
   Web of Science ®Google Scholar
• Mak LY, Seto WK, Hui RW, et al. Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval. J Viral Hepat. 2019 Jul;26(7):818–827. doi: 10.1111/jvh.13095
   PubMed Web of Science ®Google Scholar
• Yuen MF, Wong DK, Fung J, et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008 Oct;135(4):1192–1199. doi: 10.1053/j.gastro.2008.07.008
   PubMed Web of Science ®Google Scholar
• Anderson RT, Choi HSJ, Lenz O, et al. Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021 Mar;19(3):463–472. doi: 10.1016/j.cgh.2020.05.041
   PubMedGoogle Scholar
• Hara T, Suzuki F, Kawamura Y, et al. Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-naive chronic hepatitis B patients. J Viral Hepat. 2014 Nov;21(11):802–808. doi: 10.1111/jvh.12211
   PubMed Web of Science ®Google Scholar
• Ko KL, To WP, Mak LY, et al. A large real-world cohort study examining the effects of long-term entecavir on hepatocellular carcinoma and HBsAg seroclearance. J Viral Hepat. 2020 Apr;27(4):397–406. doi: 10.1111/jvh.13237
   PubMed Web of Science ®Google Scholar
• Lam YF, Seto WK, Wong D, et al. Seven-year treatment outcome of entecavir in a real-world cohort: effects on clinical parameters, HBsAg and HBcrAg levels. Clin Transl Gastroenterol. 2017 Oct 26;8(10):e125. doi: 10.1038/ctg.2017.51
   PubMed Web of Science ®Google Scholar
• Buti M, Tsai N, Petersen J, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015 May;60(5):1457–1464. doi: 10.1007/s10620-014-3486-7
   PubMed Web of Science ®Google Scholar
• Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016 Nov;1(3):185–195. doi: 10.1016/S2468-1253(16)30024-3
   PubMed Web of Science ®Google Scholar
• Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016 Nov;1(3):196–206. doi: 10.1016/S2468-1253(16)30107-8
   PubMed Web of Science ®Google Scholar
• Ghany MG, Buti M, Lampertico P, et al. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV/HDV treatment endpoints conference. Hepatology. 2023 Jun 21;78(5):1654–1673. doi: 10.1097/HEP.0000000000000431
   PubMed Web of Science ®Google Scholar
• Hui RW, Mak LY, Seto WK, et al. RNA interference as a novel treatment strategy for chronic hepatitis B infection. Clin Mol Hepatol. 2022 Jul;28(3):408–424. doi: 10.3350/cmh.2022.0012
   PubMed Web of Science ®Google Scholar
• You S, Delahaye J, Ermler M, et al. Bepirovirsen, an ASO against HBV, harbors intrinsic immunostimulatory activity via toll-like receptor 8 preclinically, correlating with clinical efficacy from the phase 2a study. J Hepatol. 2022;77:S873–S874. The International Liver Congress, EASL London, United Kingdom. [Jun 22-26 2022]. doi: 10.1016/S0168-8278(22)02041-4
   Web of Science ®Google Scholar
• Swayze EE, Freier SM, McCaleb ML, et al. inventors; IsisPharmaceuticals,Inc.,Carlsbad, CA(US), assignee. Modulation of hepatitis B virus (HBV) expression. United States; 2014.
   Google Scholar
• Han K, Theodore D, McMullen G, et al. Preclinical and phase 1 assessment of antisense oligonucleotide bepirovirsen in hepatitis B virus-transgenic mice and healthy human volunteers: support for clinical dose selection and evaluation of safety, tolerability, and pharmacokinetics of single and multiple doses. Clin Pharmacol Drug Dev. 2022 Oct;11(10):1191–1202. doi: 10.1002/cpdd.1154
   PubMed Web of Science ®Google Scholar
• Yu RZ, Warren MS, Watanabe T, et al. Lack of interactions between an antisense oligonucleotide with 2’-O-(2-methoxyethyl) modifications and major drug transporters. Nucleic Acid Ther. 2016 Apr;26(2):111–117. doi: 10.1089/nat.2015.0588
   PubMed Web of Science ®Google Scholar
• Yuen MF, Heo J, Jang JW, et al. Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial. Nat Med. 2021 Oct;27(10):1725–1734. doi: 10.1038/s41591-021-01513-4
   PubMed Web of Science ®Google Scholar
• Yuen MF, Lim SG, Plesniak R, et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection. N Engl J Med. 2022 Nov 24;387(21):1957–1968. doi: 10.1056/NEJMoa2210027
   PubMed Web of Science ®Google Scholar
• Koenig A, Bouquet J, Angelini E, et al. A primary human hepatocyte system to evaluate antisense oligonucleotide activity against clinically identified hepatitis B virus variants that contain mismatches in the bepirovirsen binding site. J Hepatol. 2023;78:S1039–S1040. EASL; Vienna, Austria. doi: 10.1016/S0168-8278(23)03130-6
   Web of Science ®Google Scholar
• Bouquet J, Elston R, Yates P, et al. Frequency of bepirovirsen binding site nucleotide polymorphisms at baseline and impact on end of treatment response to bepirovirsen (phase 2b B-Clear study). J Hepatol. 2023;78:S1162. EASL; Vienna, Austria. doi: 10.1016/S0168-8278(23)03302-0
   Web of Science ®Google Scholar
• Gadano A, Arbune M, Atsukawa M, et al. Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report. J Hepatol. 2023;78:S110. EASL; VIenna, Austria:. doi: 10.1016/S0168-8278(23)00597-4
   Web of Science ®Google Scholar
• Yuen MF, Heo J, Nahass R, et al. Preliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection. Late break abstracts. J Hepatol. 2023;78:S125. EASL; Vienna, Austria. doi: 10.1016/S0168-8278(23)00618-9
   Web of Science ®Google Scholar
• Gane E, Lim YS, Kim JB, et al. Evaluation of RNAi Therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: results from randomized clinical trials. J Hepatol. 2023 Jun 6;79(4):924–932. doi: 10.1016/j.jhep.2023.05.023
   PubMedGoogle Scholar
• Yuen MF, Lim YS, Yoon KT, et al. Safety and efficacy of VIR-2218 with or without pegylated interferon alfa in virally-suppressed participants with chronic hepatitis B virus infection: post-treatment follow up. Late break oral. J Hepatol. 2023;78:S11–S12. EASL; Vienna, Austra. doi: 10.1016/S0168-8278(23)00453-1
   Web of Science ®Google Scholar
• Yuen MF, Heo J, Kumada H, et al. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. J Hepatol. 2022 Oct;77(4):967–977. doi: 10.1016/j.jhep.2022.05.031
   PubMed Web of Science ®Google Scholar
• Gane E, Yuen MF, Kim DJ, et al. Clinical study of single-stranded oligonucleotide RO7062931 in healthy volunteers and patients with chronic hepatitis B. Hepatology. 2021 Oct;74(4):1795–1808. doi: 10.1002/hep.31920
   PubMed Web of Science ®Google Scholar
• Singh J, Salaun B, You S, et al. Cell-mediated immunity analysis to assess the characteristics of immune response to bepirovirsen: examples from the B-Clear study. J Hepatol. 2023;78:S1167–S1169. EASL; Vienna, Austraia. doi: 10.1016/S0168-8278(23)03311-1
   Web of Science ®Google Scholar
• Gane E, Jucov A, Dobryanska M, et al. Safety and antiviral activity of short-duration combinations of the siRNA, VIR-2218, with the neutralizing, vaccinal monoclonal antibody VIR-3434: post-treatment follow-up from the phase 2 MARCH trial. J Hepatol. 2023;78:S34–S35. EASL; Vienna, Austria. doi: 10.1016/S0168-8278(23)00488-9
   Web of Science ®Google Scholar
• Sonneveld MJ, Park JY, Kaewdech A, et al. Prediction of sustained response after Nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels: a multicenter study (CREATE). Clin Gastroenterol Hepatol. 2022 Apr;20(4):e784–e793. doi: 10.1016/j.cgh.2020.12.005
   PubMed Web of Science ®Google Scholar
• Jeng WJ, Chen YC, Chien RN, et al. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2018 Aug;68(2):425–434. doi: 10.1002/hep.29640
   PubMed Web of Science ®Google Scholar
• Hirode G, Choi HSJ, Chen CH, et al. Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B study). Gastroenterology. 2022 Mar;162(3):757–771 e4. doi: 10.1053/j.gastro.2021.11.002
   PubMed Web of Science ®Google Scholar
• Liu J, Li T, Zhang L, et al. The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among Asian patients with chronic hepatitis B: a systematic review. Hepatology. 2019 Sep;70(3):1045–1055. doi: 10.1002/hep.30474
   PubMed Web of Science ®Google Scholar
• Agarwal K, Lok J, Carey I, et al. A case of HBV-induced liver failure in the REEF-2 phase II trial: implications for finite treatment strategies in HBV ‘cure’. J Hepatol. 2022 Jul;77(1):245–248. doi: 10.1016/j.jhep.2022.03.006
   PubMed Web of Science ®Google Scholar
• Youssef A, Ismail M, Magee M, et al. Mechanistic pharmacokinetics/pharmacodynamics modelling of the simultaneous effects of bepirovirsen on hepatitis B surface antigen and alanine transaminase changes in chronic hepatitis B patients: phase 2b analysis to inform phase 3 decision-making. J Hepatol. 2023;77:S875. EASL; London, UK. doi: 10.1016/S0168-8278(22)02043-8
   Web of Science ®Google Scholar